The Correlation of Centromere Protein Q with Diagnosis and Prognosis in Hepatocellular Carcinoma
Kun He,Meng-yi Xie,Xiao-jin Gao,Hao Wang,Jing-dong Li
DOI: https://doi.org/10.2147/pgpm.s456965
2024-05-28
Pharmacogenomics and Personalized Medicine
Abstract:Kun He, 1, 2, &ast Meng-yi Xie, 1, 2, &ast Xiao-jin Gao, 1, 2, &ast Hao Wang, 1, 2 Jing-dong Li 1, 2 1 Institute of Hepatobiliary, Pancreatic and Intestinal Diseases, North Sichuan Medical College, Nanchong, Sichuan, People's Republic of China; 2 Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jing-dong Li, Email Introduction: Hepatocellular carcinoma (HCC) is one of the major types of liver cancer. Previous studies have shown that the centromere protein family is associated with malignant biological behaviors such as HCC proliferation. As a member of the centromere protein family, centromere protein Q (CENPQ) is closely associated with immunotherapy and immune cell infiltration in various tumors. However, the role and mechanism of CENPQ in HCC remain unclear. Methods: Multiple public databases and RT-qPCR were used to study the expression of CENPQ in HCC. Based on TCGA data, the correlation between CENPQ and clinicopathological characteristics and prognosis of HCC patients was analyzed, and its diagnostic value was evaluated. The potential biological functions of CENPQ in HCC were explored by functional enrichment analysis of differentially expressed genes. The distribution of tumor-infiltrating immune cell types was assessed using single-sample GSEA, and immune checkpoint gene expression was analyzed using Spearman correlation. Subsequently, loss-of-function experiments were performed to determine the function of CENPQ on the cell cycle and proliferation of HCC cells in vitro. Results: CENPQ was found highly expressed in HCC and correlated with weight, BMI, age, AFP, T stage, pathologic stage, histologic grade, and prothrombin time (all p < 0.05). ROC and Kaplan-Meier analyses indicated that CENPQ may be potentially used as a diagnostic marker for HCC (AUC = 0.881), and its upregulation is associated with decreased OS (p = 0.002), DSS (p < 0.001), and PFI (p = 0.002). Functional enrichment analysis revealed an association of CENPQ with biological processes such as immune cell infiltration, cell cycle, and hippo-merlin signaling deregulation in HCC. Furthermore, knockdown of CENPQ manifested in HCC cells with G0/1 phase cycle arrest and decreased proliferative capacity. Conclusion: CENPQ expression was higher in HCC tissues than in normal liver tissues. It was significantly associated with poor prognosis, immune cell infiltration, cell cycle, and proliferation. Therefore, CENPQ may become a promising prognostic biomarker for HCC patients. Keywords: centromere protein Q, biomarker, immune infiltration, cell cycle, hepatocellular carcinoma Liver cancer is one of the most frequent malignant tumors globally and has a poor prognosis and high mortality. Its most frequent histological subtype is hepatocellular carcinoma (HCC), which accounts for ~90% of cases, whereas cholangiocarcinoma and mixed subtypes account for the remaining ~10%. 1 Current therapeutic options for HCC include liver resection, liver transplantation, thermal tumor ablation, radiation therapy, transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT), chemotherapy, and immunotherapy. 2 Surgical resection is the preferred treatment for HCC patients to achieve good long-term survival. Due to the lack of characteristic clinical symptoms and rapid advancement of early-stage HCC, 70–80% of patients are in an advanced stage when detected and thus miss the opportunity for surgery. 3 Patients with advanced HCC may benefit from immunotherapy, and several immunomodulating drugs have been utilized to treat HCC. 4–6 The effectiveness of immunotherapy for cancer patients is influenced by the abundance and phenotypic distribution of immune cells in the tumor microenvironment, as well as by tumor stage. Despite recent improvements in the diagnosis and treatment of HCC, the overall prognosis of patients remains poor because of the challenging concerns of recurrence, metastasis, and tumor immunotolerance. The 5-year survival rate for advanced HCC is estimated to be less than 12%, 7 and ranges from 7–20% for cholangiocellular carcinoma. 8 Therefore, there is an urgent need to identify new therapeutic targets and better markers for early detection, treatment, and prognostic monitoring of HCC. Centromere proteins (CENPs) are crucial proteins involved in cell division and proliferation as well as the structure and function of centromeres. Abnormal expre -Abstract Truncated-
pharmacology & pharmacy